Market News AIOpen the app

Argus Research changed Elevance Health's stock rating from Hold to Buy.

OpinionRead the original at marketscreener.com
Good for ELV

Argus's move from Hold to Buy signals a more favorable view of Elevance shares. The report gives no new sales, profit, or cost figures, so it does not show that company operations improved.

ELV · Elevance Health

AI read · Good for ELV

The AI's read

This is a more favorable outside view of Elevance, which can improve confidence in its shares. The report gives no new facts about sales, profit, or costs, so the support comes from Argus's opinion alone.

Get alerts for ELV

Follow Elevance Health (ELV) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ELV
Free on the App Store and Google Play, or on the web.